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Abstract
 .Biological and analytical characterizations of permolybdate a mixture of H O and molybdate were done. Molybdate2 2
 .  .  .  .10 mM and molybdenum V chloride 3 mM did not affect gap junctional intercellular communication GJIC ,
 .phosphorylation status of connexin43 Cx43 or cellular tyrosine phosphorylation in early passage hamster embryonic cells
 .  .mainly fibroblast-like . High concentrations of H O 3–10 mM affected some of the parameters. Acidified permolybdate2 2
was clearly more stable than the unadjusted permolybdate. The maximum biological potency of acidified permolybdate was
 .  .found at a molar ratio of 2:1 H O :molybdate . The mixtures of molybdenum V chloride and H O gave a maximum2 2 2 2
  ..effect at 4:1 molar ratio H O :molybdenum V . This can be explained by decomposition of H O and by the generation2 2 2 2
of less biologically active compounds. Spectrophotometric analyses of the mixtures corroborated the biological results. The
 .  .Mo V electron spin resonance spectrum disappeared upon addition of H O to Mo V solutions, and no spectrum appeared2 2
 .  .when H O was mixed with Mo VI . Thus, permolybdate is probably diperoxomolybdate, a Mo VI compound. Regardless2 2
of the parent metal salt, the H O rmetal salt mixtures showed concentration-dependent biphasic responses with an initial2 2
decrease in GJIC followed by an increase. A dissociation between alteration in Cx43 phosphorylation status and GJIC was
obtained under certain conditions. The biological activities of permolybdate were only partially mimicked by phenylarsine
oxide, an alternative protein tyrosine phosphatase inhibitor.
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1. Introduction
The balance between protein kinases and the coun-
teracting protein phosphatases is of pivotal impor-
tance in many aspects of cellular regulation. The
protein kinases and phosphatases can with some
.exceptions broadly be classified into the
serinerthreonine or tyrosine specific enzymes. A
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number of endogenous or exogenous inhibitors and
activators of kinases or phosphatases have been very
useful to elucidate the roles of these enzymes in
cellular processes. However, the armament for affect-
 .ing the protein tyrosine phosphatases PTPases has
been rather restricted. There is now an active search
w x w xfor more inhibitors 1–4 . Vanadate 5 , molybdate
w x w x6,7 and H O 8,9 are PTPase inhibitors, but they2 2
have rather low potencies in intact cells where they
w xoften are used in mM concentrations 8,10 . Vanadate
 .and by analogy, molybdate probably acts as a phos-
w xphate analogue 11,12 . However, when a mixture of
vanadate and H O , called pervanadate, is used, a2 2
potentiated effect is achieved on PTPase inhibition
w x8 . Pervanadate has been used to study several cellu-
lar processes and enzymes regulated by tyrosine
phosphorylation. Many groups working in biological
systems have believed that pervanadate was
 . w xvanadyl IV hydroperoxide 13–20 . We investigated
this assumption in a biological system employing gap
 .junctional intercellular communication GJIC , gen-
eral cellular tyrosine phosphorylation, and altered
phosphorylation status of the gap junction channel
 . w xprotein, connexin43 Cx43 21 . In accordance with
data from inorganic chemistry, our results suggested
 .that pervanadate is diperoxovanadate V . This has
implications for the optimal generation of the com-
pound.
Presently, 13 connexin genes have been cloned
from mammals. The connexins show tissue-specific
expression. Cells in culture often express Cx43, a
connexin found in the heart, smooth muscles of
different tissues, astrocytes, fibroblasts and several
w xother cell types 22 . The gap junction channels per-
mit the diffusion of water soluble molecules )1000
.Da between the cytoplasms of neighboring cells,
although the view of the channels as non-selective
w xpores may be too simplified 23,24 . GJIC is assumed
to be involved in the regulation of growth, develop-
w xment and differentiation 25,26 . Cancer cells often
w xpossess aberrant GJIC 25 . When cancer cells not
expressing connexins are transfected with the rele-
vant connexin gene, they show decreased malignant
w xpotential 27–30 . This suggests the possibility of
tumor suppressing activity of connexins.
Permolybdate, a mixture of molybdate and H O ,2 2
w xpartially mimics both insulin-like 31 and
w xinterferong-like 32 effects of pervanadate. Both per-
vanadate and permolybdate induce tyrosine phospho-
 .rylation of Cx43 Mikalsen et al., submitted . This
has previously only been found in cells transfected
w x w xwith the v-src 33–35 or v-fps 36 oncogenes. Thus,
these compounds might be tools to study the regula-
tory importance of tyrosine phosphorylation on GJIC.
It was therefore of interest to characterize per-
molybdate in greater detail both with regard to its
nature and its biological activity using GJIC and
phosphorylation as parameters. The biological results
are compared with spectrophotometric and electron
 .spin resonance ESR analyses. Furthermore, we in-
vestigated if the biological responses of permolybdate
could be mimicked by an alternative membrane-per-
meable PTPase inhibitor, phenylarsine oxide.
2. Materials and methods
2.1. Chemicals
 .Lucifer Yellow CH, catalase 2= crystallized and
 .phenylarsine oxide PAO were purchased from
 .Sigma St. Louis, MO . Hydrogen peroxide was ob-
 .tained from Merck Darmstadt, Germany . Sodium
 .  .molybdate Na MoO P2H O and molybdenum V2 4 2
 .chloride MoCl were obtained from Aldrich5
 .Steinheim, Germany . PAO was dissolved in
dimethyl sulfoxide to 30 mM.
2.2. Cell cultures
Primary cell cultures from Syrian hamster Wright,
.  .Chelmsford, Essex, UK embryos SHE cells were
prepared at 14 days of gestation and cryopreserved in
w xliquid nitrogen 37 . The SHE cells are mainly fibrob-
last-like, and they were used between passages 2 and
10. No differences in responses were found between
early and later passages, but different preparations of
 .cells could show small 3-fold differences in concen-
tration-dependent responses. Many of the experi-
ments have been run separately in at least two prepa-
rations usually at least three times in each prepara-
.tion of SHE cells, each time resulting in identical
conclusions. The cells were grown in Dulbecco’s
modified Eagle’s medium Bio-Whittaker, Walk-
. ersville, NY with 10% fetal bovine serum GIBCO,
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.Paisley, Scotland . They were maintained at 378C in
10% CO atmosphere. No antibiotics were used.2
2.3. Preparation of per-compounds
For simplicity, we refer to the compounds as ‘per-
 .  .molybdate VI ’ and ‘permolybdenum V ’ depending
on the parent metal salt. ‘Permolybdate’ will be used
a common term for the biologically active complex
of either molybdenum salt and H O .2 2
H O was titrated with potassium permanganate to2 2
adjust the concentration. The metal salts were dis-
solved in water to 1 M. Note that molybdenum
chloride reacts violently with water, and should be
dissolved in a fume-hood. We do not dismiss the
possibility that redox reactions occur during solubi-
 .lization of molybdenum V chloride, generating some
 .  .  .Mo IV andror Mo III . Permolybdate VI and per-
 .molybdenum V were made in 100 mM stock solu-
tions with different stoichiometric ratios of H O ,2 2
e.g., 100 mM H O for the 1:1 stoichiometry, 2002 2
mM H O for the 2:1 stoichiometry, etc. The ratios2 2
will always be written as the molar stoichiometric
amount of H O :metal salt. The metal salt and H O2 2 2 2
were generally co-incubated for 15 min before addi-
tion to the cells. Catalase was added in some experi-
ments, but usually not.
pH-adjustments of the mixtures were done in a
 .number of experiments. HCl 3 M was added to the
molybdate solution before addition of H O . The2 2
resulting mixtures are called ‘acidified molybdate’
 .and ‘acidified permolybdate VI ’. Other details are
given in the text. The concentration of the parent
metal salt is always considered as the concentration
of the per-compound.
2.4. Gap junctional intercellular communication
For GJIC experiments the cells were seeded in 35
mm dishes and grown for 2 or 3 days until confluent.
w xGJIC was measured as described previously 38 by
microinjection of Lucifer Yellow 10% wrv in 0.3 M
.lithium chloride into single cells using a Nikon
Diaphot TMD microscope and a Narishige Tokyo,
.Japan micromanipulator coupled to a pressure con-
trol unit Eppendorf 5242; Eppendorf, Hamburg, Ger-
.many . Five minutes after injection, the cells were
fixed in 2% formalin in PBS and the number of
dye-coupled cells was counted using the epifluo-
rescence equipment and a modified fluorescein filter
 .block 435, 510 and 520 nm filters on the same
microscope as above. The cells were exposed as
indicated in the text and legends.
2.5. Western blotting
The cells were grown as described for GJIC. They
were washed in PBS, and scraped into 200 ml elec-
trophoresis sample buffer. The cell suspension was
sonicated to shear DNA. Discontinuous SDS-PAGE
w xwas performed as described by Laemmli 39 in the
 .Bio-Rad Melville, NY Mini Protean system, using
w x7.5% acrylamide gels as previously described 15 .
The separated proteins were blotted onto nitrocellu-
lose membranes. Cx43 was detected by a rabbit
anti-Cx43 antiserum, goat anti-rabbit IgG conjugated
 .to horseradish peroxidase Bio-Rad , and develop-
ment with 4-chloro-1-naphthol as described by the
 .supplier Bio-Rad . Cellular phosphotyrosine was de-
tected by the monoclonal antibody 4G10 Upstate
.Biotechnology, Lake Placid, NY , a goat anti-mouse
 .IgG conjugated to alkaline phosphatase Bio-Rad ,
and development with 5-bromo-4-chloro-3-indoyl
phosphate and nitroblue tetrazolium as described by
 .the supplier Bio-Rad . The specificities of the anti-
 .bodies were checked. The Cx43 peptide 10 mgrml
w xabolished the recognition of Cx43 on the blots 15 .
The goat anti-rabbit antibodies did not cause any
 .unspecific bands not shown . Phosphotyrosine caused
a concentration-dependent competition evident from
10 mgrml, and it was nearly complete at 1 mgrml
even for treatments that maximally increased phos-
photyrosine 30 min exposure to 30 mM pervanadate
.or 300 mM permolybdate; not shown . In some ex-
periments, the goat anti-mouse IgG alkaline phos-
phatase conjugate gave a weak band at around 130
kDa. In addition a weak reaction was found in two
bands at around 80 kDa corresponding to one of the
.very strong bands in the phosphotyrosine blots after
treatments that maximally increased phosphotyrosine
 .not shown .
2.6. Electron spin resonance spectroscopy
 .The electron spin resonance ESR spectra were
obtained using a home built X band reflection ESR
w xspectrometer 40 . The solution to be analyzed was
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transferred to a 50 ml ESR quartz cuvette. The
positions of the ESR peaks were monitored using an
EIP 575 Microwave Counter and an NMR field
marker, indicating every 30 G. The field was modu-
lated with 110 kHz and an amplitude of 10 G. Most
scans were performed with a field of 500 G swept in
3 min, using no external filtering.
2.7. Spectrophotometry
Absorbance spectra were obtained on a Hewlett
Packard 8450A diode array spectrophotometer. Since
 .  .a dilute 0.5 mM solution of molybdenum V was
found to be sensitive for dissolved oxygen in water or
 .buffers not shown , the solutions were degassed and
flushed with N before use. The solutions were also2
flushed with N during the preparations for the mea-2
surements.
2.8. Statistics for GJIC experiments
All groups that were statistically compared were
run in the same experiments. The statistics were
performed on the raw data. The level of significance
was calculated two-sided by a computerized t-test
with Welch correction Instat; GraphPad Software,
.San Diego, CA . The data are shown as mean"
S.E.M. for n injections. For easier comparison be-
tween different treatments, the data shown in the
curves were transformed to percentage of control
i.e., the mean of the control is defined as the 100%
.GJIC level . Generally, P-0.01 was achieved at
GJIC levels corresponding to 75% and 125% of
control if n;30, and 70% and 130% of control if
n;20.
3. Results
3.1. GJIC
Based on our previous results with the related
w xcompound, pervanadate 15,21 , we chose 1 h as the
standard exposure time. The single compounds
 .molybdate, molybdenum V , H O and the mem-2 2
brane-permeable PTPase inhibitor, PAO, were first
w xstudied. In accordance with previous results 38 ,
 .H O increased GJIC at high concentrations Fig. 1 .2 2
Fig. 1. Dose-responses of H O and PAO on GJIC. Confluent2 2
 .  .SHE cells were exposed for 1 h to I H O or ^ PAO2 2
before assessing GJIC by microinjection and dye transfer as
 .described in Section 2. The control level 100% corresponded to
40–50 communicating cells. ns28–75.
 .PAO caused decreased GJIC at 100 mM Fig. 1 , but
it was very toxic to the cells as evidenced by detach-
ment of some cells at 10 and 30 mM, but not at 100
 .m M . Sodium m olybdate Fig. 2A and
 .  .molybdenum V chloride Fig. 2B did not decrease
GJIC at 10 and 3 mM, respectively.
Per-compounds were made from the molybdenum
salts, using different stoichiometric ratios of
 .H O :metal salts. Permolybdate VI caused a bipha-2 2
sic dose-response curve for GJIC with the 2:1 and 5:1
ratios slightly more potent than the 1:1 ratio Fig.
.2A . The maximum decrease in GJIC occurred at
1–3 mM, while 10 mM was less effective. Immedi-
ately after mixing H O and molybdate, the solution2 2
turned red-brown, but the color was gradually lost
concurrently with an extensive development of gas. If
 .catalase was added to the permolybdate VI mixture,
the red-brown color disappeared rapidly, and also the
 .biological effect of the mixture not shown . The
strong color changes, the development of gas and the
high susceptibility to catalase suggested an unstable
compound. Therefore experiments were also done
with the 5:1 stoichiometry with exposure to the cells
immediately after mixing of H O and molybdate.2 2
 .The permolybdate VI solution was now clearly more
toxic, and many cells detached at 3 and 10 mM after
1 h. The decrease in GJIC was strongest at 300 mM,
 .and with an increase in GJIC at 1 mM Fig. 2A .
Thus, the dose-response curve was moved a half
 .order of magnitude to the left when permolybdate VI
was added to the cells immediately after mixing.
It was investigated if biologically active permolyb-
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 .  .Fig. 2. Effect of Mo VI , Mo V and their percompounds on
GJIC. Confluent SHE cells were exposed for 1 h to molybdenum
salts mixed with different ratios of H O . GJIC was then as-2 2
sessed by microinjection and dye transfer as described in Section
 .2. With one exception v , the mixtures of H O and metal salt2 2
were preincubated for 15 min before addition to the cells. B,
metal salts; I, 1:1 ratio of H O :metal salt; \ and stippled line,2 2
1.5:1 ratio of H O :metal salt; ^, 2:1 ratio of H O :metal salt;2 2 2 2
l, 2.5:1 ratio of H O :metal salt; e, 3:1 ratio of H O :metal2 2 2 2
salt; ‘ and dotted line, 5:1 ratio of H O :metal salt; v, 5:1 ratio2 2
of H O :molybdate added to the cells immediately after mixing2 2
 .of compounds. A, Unadjusted Mo VI and unadjusted permolyb-
 .  .  .date VI . ns20–41. B, Mo V and permolybdenum V . The
 .curves for the 0.5:1 and the 4:1 ratios of H O :Mo V are not2 2
 .shown. The 0.5:1 ratio of H O :Mo V behaved nearly identi-2 2
 .  .cally to Mo V not studied at 3000 mM . The 4:1 ratio behaved
 .nearly identically to the 5:1 ratio of H O :Mo V . ns18–40. C,2 2
 .  .acidified Mo VI and acidified permolybdate VI . The curves for
the 3:1 and 4:1 ratios of H O :acidified molybdate are not2 2
shown. Both behaved nearly identically to the 2:1 and 5:1 ratios
of H O :acidified molybdate. ns19–34.2 2
 .date could be obtained using molybdenum V chlo-
ride as a starting point. The dark red-brown stock
 .  .  .solution of Mo V 1 M was strongly acidic pH-1 ,
but it did not affect GJIC in concentrations up to 3
 .mM Fig. 2B . To avoid possible interference of the
low pH with GJIC, the highest concentration of
 .permolybdenum V was limited to 1 mM. Some de-
velopment of gas occurred after the mixing of H O2 2
 .and molybdenum V , but it was clearly less than for
 . molybdate. Permolybdenum V 0.5:1 ratio, colorless
.after preincubation did not affect GJIC, while the 1:1
 .ratio yellow with a slight green hue caused a de-
crease at 300 to 1000 mM. Increasing ratios of H O2 2
caused a left-shift in the dose-response with a devel-
opment of a biphasic response curve similar to that
 . found for permolybdate VI 5:1, added to the cells
.immediately after mixing both in shape and molar
 .potency. The maximal potency of permolybdenum V
was achieved at a ratio between 3:1 and 4:1
  ..H O :Mo V .2 2
These results showed that the per-compounds of
both molybdenum salts were more potent than the
parent compounds to inhibit GJIC. Furthermore, the
 .inhibition of GJIC by permolybdate VI or permolyb-
 .denum V cannot be explained by the concentration
of H O .2 2
We have recently shown that pH-adjustments
markedly could affect the ratio of H O needed to2 2
generate biologically active pervanadate from vanadyl
w xsulfate 21 . A similar investigation was made for
molybdate. When H O was added to molybdate, the2 2
pH increased by about 2 units and there was develop-
ment of gas. Therefore molybdate was acidified with
HCl before addition of H O . When more than2 2
equimolar amounts of HCl had been added, some of
the properties of the H O rmolybdate mixture2 2
changed abruptly. Specifically, the pH decreased upon
addition of H O , no generation of gas occurred, and2 2
the resulting solution was yellow with a slight green
hue. Thus, in the following experiments, a molar
ratio of 1.2 HCl:1 molybdate was kept constant, and
the ratio H O :molybdate was varied. At a 1:1 ratio,2 2
there was a significant decrease in GJIC at 300 to
 .1000 mM, and an increase at 3000 mM Fig. 2C .
The 2:1, 3:1, 4:1 and 5:1 ratios all had similar and
significant decreases in GJIC at 100 and 300 mM,
 .and with increases at 1000 mM Fig. 2C . These
results suggested that the maximal potency of per-
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 .Fig. 3. Time-responses of acidified permolybdate VI on GJIC.
 .  .  .Cells were exposed to ‘ 100 mM, e 300 mM or ^ 1000
 .mM acidified permolybdate VI , and GJIC was assessed after 15,
30, 60, 90 and 120 min. ns24–60.
 .molybdate VI was achieved when a molar ratio of
2:1 of H O :acidified molybdate was used.2 2
Due to the peculiar biphasic dose-response curve,
time-responses for 100, 300 and 1000 mM of acidi-
 .  .  .fied permolybdate VI 2:1 were studied Fig. 3 .
 .The low concentration 100 mM showed a moderate
decrease in GJIC at 30–60 min, but it was normal-
ized at 90–120 min. The middle concentration 300
.mM showed the optimal inhibition of GJIC at 30
min. Apparently a recovery of GJIC had started at 60
min, and it was normalized at 90–120 min. The high
 .concentration 1000 mM did not significantly affect
GJIC at 15–30 min, but there was a slight inhibition
at 60 min. There was a highly significant inhibition
of GJIC after 90–120 min. It should be noted that the
response obtained in different batches of SHE cells
could be shifted somewhat up or down both with
regard to concentration andror time, but the de-
scribed tendencies were always found.
3.2. ESR spectroscopy of molybdenum compounds
ESR experiments were performed to assess the
 .  .effect of addition of H O to Mo V and Mo VI2 2
 .solutions. Due to the varying width of the Mo V
w xESR signals 41 , concentrations in the range of
 .10–200 mM were used. Mo VI lacks unpaired elec-
trons, and thus gave no ESR signal, neither before
 .  .Fig. 4A nor after the addition of H O Fig. 4B .2 2
 .When cysteine was added to the Mo VI solution, a
pH dependent ESR signal was detected after incuba-
 .  . tion, indicating a reduction of Mo VI to Mo V Fig.
.4C . At pHs8, the signal had a g-factor of 1.98 and
 .a peak-to-peak width of 13 G at the central Mo V
peak, accompanied by the weak six-line pattern from
the Is5r2 Mo95,97 isotopes. Subsequent addition of
H O gave a concentration-dependent decrease in the2 2
 .  .Mo V signal Fig. 4D and E . At pHs3, broader
 .ESR spectra were observed not shown . Some pre-
cipitate formed under these conditions. When
equimolar concentrations of EDTA were added to
avoid precipitation, other ESR signals appeared both
at pHs3 and 8. These signals differed from the
 .signal in Fig. 4C mainly by their position gs1.94 .
 .The Mo V -EDTA complexes, however, reacted
slowly with H O , as inferred from the retarded2 2
decrease of their ESR signals upon H O addition. It2 2
was concluded that cysteine, but not H O , was able2 2
 .  .to reduce Mo VI to Mo V .
Fig. 4. ESR spectra of molybdenum compounds in aqueous
solution. The field was swept from 3250 to 3750 G in 3 min with
10 G modulation at a frequency of 9465 MHz. A, hexavalent
 .molybdenum 100 mM Na MoO at pH 3. B, 100 mM Na MoO2 4 2 4
at pH 3 was incubated with 200 mM H O for 15 min. C,2 2
incubation of 200 mM Na MoO with 500 mM cysteine at 658C2 4
for 15 min at pH 8. D, the mixture from C was added 50 mM
 .H O i.e., 0.25:1 H O :Mo and incubated for 15 min at room2 2 2 2
temperature. E, the mixture from C was added 150 mM H O2 2
 .i.e., 0.75:1 H O :Mo and incubated for 15 min at room temper-2 2
 .ature. F, Pentavalent molybdenum 30 mM MoCl was incu-5
bated at 658C for 15 min at pH 3. G, the solution from F was
  ..added 9 mM H O i.e., 0.3:1 H O :Mo V . H, the solution2 2 2 2
  ..from F was added 30 mM H O i.e., 1:1 H O :Mo V .2 2 2 2
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The ESR spectrum of 30 mM MoCl at pHs35
was not completely stable at room temperature. It
evolved slowly into the form shown in Fig. 4F, which
also could be achieved after incubation at 658C for 15
min. The spectrum consisted mainly of two peaks
with gs1.91 and gs1.93. The corresponding radi-
cals were susceptible to H O , as seen after addition2 2
 .  . of 9 mM 0.3:1 and 30 mM 1:1 H O Fig. 4G and2 2
.H . As above, we interpreted this as an oxidative
 .  .reaction of Mo V to Mo VI . When using EDTA,
we obtained ESR signals similar to the ones observed
 .in the Mo VI -cysteine-EDTA system, and again these
 .are only very slowly decreased by H O not shown .2 2
Thus, the present results indicate that H O will not2 2
 .  .reduce Mo VI to Mo V under widely varying con-
ditions such as varying pH in the range 1–10, vary-
ing incubation time and temperature, adding EDTA
andror PBS, and degassing the solution with nitro-
gen.
3.3. Spectrophotometry of permolybdenum com-
pounds
 .The per-compounds 100 mM Mo were generated
in water as described in Section 2, using different
 .ratios of H O ranging from 0:1 to 5:1 H O :Mo .2 2 2 2
The compounds were then diluted to 0.5 mM in 50
 .mM glycine buffer pH 3.0 , and the spectra were
acquired. The absorbance spectra of acidified molyb-
 .  .  .date VI Fig. 5, trace 4 and H O Fig. 5, trace 92 2
were characterized by a high absorbance at lower
wavelenghts and a gradual and smooth decrease to 0.
If the H O rmolybdate mixture was a simple mix-2 2
 .ture without any reactions we should expect the
resultant spectrum to be the sum of the two spectra.
Clearly, this did not occur. When H O was added to2 2
acidified molybdate, the absorbance below approx.
290 nm was reduced, and a broad peak with ab-
sorbance maximum at about 310 nm was generated
 .Fig. 5, traces 5, 6 and 7 . Both the reduction in
absorbance below 290 nm and the growth of the peak
at 310 nm were fully developed when 2 molar equiv-
 .alents of H O had been added Fig. 5, trace 8 .2 2
There were minimal changes in the spectrum when
 .H O was further increased to 5:1 not shown .2 2
Similar results were obtained when water was used
instead of the glycine buffer.
 .Molybdenum V showed a high absorbance at low
 .Fig. 5. Spectral changes 220-420 nm upon addition of H O to2 2
 .  .  .Mo V or acidified Mo VI . Acidified permolybdate VI and
 .  .permolybdenum V both 100 mM in water were generated as
described in Section 2 using different ratios of H O . The2 2
percompounds were incubated for 15 min, diluted to 0.5 mM in
50 mM glycine pH 3.0, and the spectra acquired. Trace 1
 .  .  .  .  .dotted , Mo V . Trace 2 stippled , permolybdenum V 0.125:1 .
 .  .Trace 3, permolybdenum V 0.25:1 . Trace 4, identical traces of
 .  .  .permolybdenum V 0.5:1 and molybdate. Traces 5 dotted , 6
 .  .  .stippled , 7, and 8 dotted , acidified permolybdate VI 0.5:1,
1:1, 1.5:1, and 2:1, respectively. Trace 9, 1.5 mM H O . Not2 2
shown is the trace of the 5:1 ratio, which behaved identically to
 .the 2:1 ratio of H O :acidified molybdate trace 8 .2 2
 .wavelenghts -230 nm and a clear peak at about
 .294 nm Fig. 5, trace 1 . Addition of H O to2 2
 .molybdenum V caused this peak to degenerate in a
concentration-dependent manner Fig. 5, traces 2 and
.3 . When less than 0.5 molar equivalents of H O2 2
was added, the solution turned dark blue probably
due to molybdenum blue, a colloidal solution of
 .  . .Mo V and Mo VI hydroxo complexes , and a dark
blue precipitate formed upon standing. This may
partially explain the unexpected behavior of the spec-
 .tra traces 2 and 3 compared to traces 1 and 4 at low
 .wavelengths below 260 nm and at higher wave-
 .lengths above 320 nm . When 0.5 molar equivalents
of H O was added, the mixture became colorless2 2
upon incubation, and the resultant spectrum was iden-
 .tical to the molybdate spectrum Fig. 5, trace 4 . It is
 .therefore likely that 1 molar equivalent of Mo V was
 .oxidized to Mo VI by 0.5 molar equivalents of
H O . Further adding of H O generated a peak of2 2 2 2
absorbance of the same shape, height and wavelength
 .as found for permolybdate VI . However, as best
evidenced by the decrease in absorbance at 220 nm,
the spectral changes were fully developed only at
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 .ratios above 3:1 not shown . Thus, the observed
 .changes in the acidified permolybdate VI and per-
 .molybdenum V spectra are in good agreement with
the GJIC results.
 .Based on the results for permolybdate VI we
 .would theoretically have expected permolybdenum V
to achieve the final product at a ratio of 2.5:1. To
study if this difference could be due to the low pH of
 .  .the molybdenum V solution, permolybdate VI was
generated in 1 M HCl, and analyzed as above. The
2:1 ratio was now not sufficient to fully achieve the
final spectrum under these conditions, while the 3:1
ratio showed a spectrum that appeared to be the final
 .not shown .
3.4. Phosphorylation
Two parameters of phosphorylation were analyzed,
the general cellular tyrosine phosphorylation and al-
tered phosphorylation status of Cx43. The results are
 . only described for acidified permolybdate VI 2:1
.ratio , but most of the combinations between H O2 2
 .and molybdate or molybdenum V have been studied
for their effect on the two parameters in at least two
 .cell batches several experiments in each cell batch .
PAO induced a slight increase in cellular phospho-
tyrosine detectable already at 0.3–1 mM, but the
increase was moderate even at 100 mM Fig. 6A,
.  .upper panel . Molybdate 1–10 mM did not cause
Fig. 6. Cellular tyrosine phosphorylation and alterations in Cx43 band pattern induced by PAO, molybdate, H O and permolybdate.2 2
 .Confluent SHE cells in 35 mm dishes were exposed to A, PAO or molybdate Mo ; and B, H O or acidified permolybdate 2:12 2
  ..  .H O :Mo VI aPMo at the indicated concentrations for 1 h. The samples were made, and the electrophoresis and Western blotting2 2
 .  .were performed as described in Section 2. The samples were analyzed both for upper panels tyrosine phosphorylation and lower panels
Cx43. P, prestained standards with apparent molecular mass in kDa to the left. C, unexposed control cells.
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detectable increase in tyrosine phosphorylation Fig.
.6A, upper panel . H O slightly increased cellular2 2
phosphotyrosine at 3 mM, and at 10 mM there was a
 .clear increase Fig. 6B, upper panel . Acidified per-
 .  .molybdate VI 2:1 slightly increased phospho-
tyrosine at 100 mM, but there was a massive increase
 .at 300 mM Fig. 6B, upper panel . The amount of
phosphotyrosine decreased somewhat at 1000 and
 .3000 mM Fig. 6B, upper panel . A similar decrease
 .was seen also for permolybdenum V under condi-
tions that caused the ‘second phase’ increase in GJIC
 .not shown .
In many cell types, including SHE cells, Cx43
normally shows a pattern of three major bands, a
 .lower non–phosphorylated NP species and two up-
 . w xper phosphorylated species P1rP2 15 . PAO mini-
mally altered the band pattern of Cx43 Fig. 6A,
.lower panel . There was no detectable change in
Cx43 band pattern caused by molybdate Fig. 6A,
.lower panel . H O caused a clearly altered Cx432 2
 .band pattern at 10 mM Fig. 6B, lower panel . The
NP band decreased in intensity, and an increasing
smear occurred in the area of the P1rP2 bands.
 .  .Acidified permolybdate VI 2:1 caused no changes
in the Cx43 band pattern at 1 h of exposure to 10 and
 .30 mM Fig. 6B, lower panel . At 100 mM, the P2
band decreased somewhat in intensity and the NP
band became more blurred, mainly due to the appear-
ance of a new band immediately above NP. At 300
mM, there was a strong change in the Cx43 band
pattern characterized by the disappearance of the NP
band and an increased smear in the area of the P1rP2
bands. No clear P1rP2 bands could be seen through
the smear. Further increasing the concentration of
 .acidified permolybdate VI to 1000 and 3000 mM,
caused the smear to move downwards to a relatively
wide band slightly below the P1 band Fig. 6B, lower
.panel . Concurrently, somewhat indistinct NP, P1 and
P2 bands reappeared with lower intensity.
Fig. 7. Time-course of alterations in Cx43 band pattern and
cellular tyrosine phosphorylation induced by permolybdate. Con-
fluent SHE cells in 35 mm dishes were treated with A, 100; B,
300; or C, 1000 mM permolybdate. The samples were made at
the indicated times, and the electrophoresis and Western blotting
were performed as described in Section 2. The samples were
 .analyzed both for upper panels tyrosine phosphorylation and
 .lower panels Cx43. P, prestained standards with apparent
molecular mass in kDa to the left. C, unexposed control cells.
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3.5. Time-course of phosphorylation
The time-course of alterations in cellular tyrosine
phosphorylation and Cx43 band pattern were studied
using 100, 300 and 1000 mM acidified permolyb-
 .  .  .date VI 2:1 ratio Fig. 7A–C, upper panels . An
increase in cellular protein tyrosine phosphorylation
was clearly detectable after 1 min for all three con-
centrations of permolybdate. The lowest concentra-
 .tion 100 mM reached a maximum amount of phos-
photyrosine after 10–30 min, followed by a promi-
nent decrease approaching the control level at 60–90
 .min Fig. 7A, upper panel . An unidentified protein
of about 160 kDa remained strongly tyrosine phos-
phorylated. The period of phosphotyrosine maximum
was more extended at 300 mM acidified permolyb-
 .date VI , but most experiments indicated a small
 .decrease at 90 min Fig. 7B, upper panel . The
decrease in phosphotyrosine was prominent at 120
min. There was no clear decrease in phosphotyrosine
at 120 min in cells exposed to 1000 mM acidified
 .  .permolybdate VI Fig. 7C, upper panel .
The Cx43 band pattern also showed reversible, but
 .complex, changes. The initial changes up to 30 min
were relatively similar for the three concentrations of
 . acidified permolybdate VI Fig. 7A–C, lower pan-
.els . The NP band showed a slight decrease in inten-
sity at 5 min of exposure, and blurred band appeared
just below P1. The intensity of the NP band contin-
ued to decrease at 10–30 min, and a smear developed
in the P1rP2 area. Subsequently, the NP and P1
bands of Cx43 reappeared again in a more 300 mM,
.  .120 min or less 100 mM, 60 min blurred variant.
A clear P2 band only reappeared at 120 min of
 . exposure to 100 mM acidified permolybdate VI Fig.
.7A, lower panel . The smear in the P1rP2 area
 . caused by 1000 mM acidified permolybdate VI Fig.
.7C, lower panel seemed less pronounced compared
 .to 300 mM Fig. 7B, lower panel at 15–30 min as
the P1 and P2 bands can be seen through the smear.
Furthermore, the smear moved downward at 60–90
min, and seemed to concentrate in a broad band just
 .below P1 Fig. 7C, lower panel . The NP band
reappeared at 90–120 min. Interestingly, the de-
scribed changes in Cx43 band pattern were not al-
ways correlated with decreases in GJIC. This is
further discussed below.
4. Discussion
4.1. The nature of permolybdate
It has previously been asserted that the potent
biological activity of the mixture between H O and2 2
  ..vanadate V V was due to the generation of
 .  .vanadyl IV hydroperoxide see Section 1 . However,
in line with data from inorganic chemistry, studies in
a biological system suggested that pervanadate is
w xdiperoxovanadate 21 . We have now investigated the
nature of the biologically active compound of per-
molybdate. Permolybdate could be generated from
 .  .both Mo V and Mo VI , but more H O was needed2 2
 .  .to generate it from Mo V relative to Mo VI . Spec-
 .trophotometrically, the Mo V spectrum disappeared
when adding H O , and a spectrum identical to2 2
 .Mo VI was obtained at a ratio of 0.5:1
  ..H O :Mo V . Visually, the mixture became color-2 2
less at the 0.5:1 ratio. This is the expected result if
 .  .H O oxidized Mo V to Mo VI . Consistent with2 2
w x .previous results 41 and references therein , the
 .Mo V ESR spectrum is highly dependent on the
properties of the solution complexing and chelating
.agents, pH, concentration . Regardless of how the
 .Mo V ESR spectrum is generated, it disappears when
 .H O is added, and no Mo V ESR spectrum appears2 2
 .when Mo VI is incubated with H O . Thus, both the2 2
biological and analytical approaches indicate that per-
 .molybdate is a Mo VI compound. This is in accor-
w xdance with previous inorganic studies 42 .
How many peroxide ligands are needed to generate
the biologically active permolybdate? Permolybdate
 .species with 4:1, 3:1, 2:1 and 1:1 ratios H O :Mo2 2
w xhave been prepared 42 . The red and unstable 4:1
w xspecies is most prominent at alkaline pH 43 . It
w xdecomposes with the development of oxygen 42 .
This description fits well with the behavior when
H O is added to un-adjusted molybdate. However, a2 2
yellow solution with a weak green hue is directly
formed when H O is added to acidified molybdate,2 2
and the gas development is largely abrogated. Under
this condition, there is a clear difference in the bio-
logical potencies of the 1:1 and 2:1 ratios, while there
is little difference between the 2:1 and 5:1 ratios both
in the GJIC and phosphorylation studies. Conse-
 .quently, the 2:1 ratio of H O :Mo VI is close to the2 2
( )S.-O. Mikalsen, O. KaalhusrBiochimica et Biophysica Acta 1356 1997 207–220 217
ratio causing maximum biological activity of per-
molybdate. The spectrophotometric analysis supports
this conclusion since the major changes in the spec-
trum were finalized at a ratio of 2:1 when using
acidified molybdate.
We had expected that 2.5 molar equivalents of
H O would be needed to generate the biologically2 2
 .active permolybdate from molybdenum V , in paral-
w xlel to our results for pervanadium compounds 21 .
 .However, permolybdenum V showed a somewhat
  ..lower potency at the 3:1 H O :Mo V ratio com-2 2
pared to the 4:1 ratio in the GJIC assay. This could
suggest that 3 H O are needed to generate the2 2
biologically active permolybdate under the assump-
 .tion that 0.5 H O is needed to oxidize 1 Mo V to2 2
 .Mo VI . Several explanations may be offered for the
difference between the expected and the observed
potency. H O is partly decomposed by molybde-2 2
 .num V as evidenced by the gas development in the
 .  .mixture. Furthermore, if some Mo IV or Mo III
 .exists in the solution see Section 2 , more H O will2 2
be needed to generate the active compound, although
in this case more than 0.5 H O should be needed for2 2
 .the oxidation to Mo VI . In addition, the molybde-
 .  .num V chloride solution is strongly acidic pH-1 ,
which favors the generation of the monoperoxo-
w xspecies 43 , and thus more H O might be needed to2 2
force the generation of the diperoxo-species. The
monoperoxo-species could well be less biologically
active than the diperoxo-species.
In conclusion, diperoxomolybdate is probably the
active compound when generated under slightly acidic
conditions. Diperoxomolybdate has previously been
w xdescribed as a yellow compound 42 . The peroxo-
 . w xligand forms a triangular Mo O structure 42 , which2
readily explains the decrease in pH when H O is2 2
added to slightly acidic molybdate. While the
MoO 2y-ion is tetrahedral, diperoxomolybdate4
is probably seven-coordinated with a pentagonal
w xbipyramidal structure 43,44 . We cannot dismiss
the possibility that the compound exists and is
active as a dimer, tetraperoxodimolybdate
w  .  . x2y w xMo O O H O 43,44 . This species is most2 3 2 4 2 2
w xprominent at pH 2–5 43 , which is the pH range
used during the generation of the acidified permolyb-
date. For the corresponding vanadium compounds,
the dimer is prominent at high concentrations and the
w xmonomer at low concentrations of vanadate 45 . Our
w xconclusion is in contrast to that of Li et al. 31 who
found 3 H O needed to fully generate permolyb-2 2
date. We believe the discrepancy is caused by the
their procedure used to generate permolybdate, which
seems to be similar to our ‘unadjusted
 .permolybdate VI ’.
4.2. Alterations in phosphorylation and GJIC
The parent metal ions did not cause increased
tyrosine phosphorylation or decreased GJIC in SHE
cells. The PTPase inhibitor PAO has been shown
active in the concentration range of 1–50 mM in
w xother cellular systems 46–48 . We found it to in-
crease the amount of phosphotyrosine to a limited
extent at low concentrations, but it was without effect
on GJIC at these concentrations. PAO can be partly
w xcell specific 49 , and it may affect cellular adhesion
w x50 . In some cases, the strongest effect of PAO occur
w xat intermediate concentrations 51 , similar to our
observations of cell detachment. In contrast to PAO
 .and the parent metal salts, H O 10 mM and per-2 2
 .molybdate 300 mM induced massive increases in
cellular tyrosine phosphorylation after 1 h exposures.
It is therefore likely that PAO does not inhibit the
same complement of enzymes as do permolybdate,
 .pervanadate or H O , or less likely that the latter2 2
compounds are able to inhibit the enzymes to a
greater extent than PAO.
Permolybdate is a novel inducer of cellular phos-
w xphotyrosine. Recently, Li et al. 31 found permolyb-
date to mimic the insulin-like effects of pervanadate
in rat adipocytes, including the inhibition of PTPase
activity. They found permolybdate to be about 100
times less potent than pervanadate, while in our
system the difference is approximately 30-fold. This
difference could be due to a less efficient generation
of the active compound in their experiments.
The biological response to permolybdate can
clearly be distinguished from that of pervanadate by
the concentration-dependent biphasic GJIC-response.
Apparently, there is a faster onset and removal of
cellular phosphotyrosine caused by permolybdate than
 w x.by pervanadate present results and Ref. 21 . We do
not know of other agents than permolybdate and in
.some cell batches, also H O that cause a concentra-2 2
tion-dependent biphasic response, with a decrease in
 .GJIC followed by a partial normalization. The sim-
( )S.-O. Mikalsen, O. KaalhusrBiochimica et Biophysica Acta 1356 1997 207–220218
plest explanation for the biphasic response caused by
permolybdate is that two PTPases with opposite func-
tions are involved. Normally they balance each other,
but one of them could be more sensitive for per-
molybdate than the other. Inhibition of the most
 .sensitive phosphatase by 300 mM permolybdate
would cause GJIC to decrease, while a higher con-
 .centration 1000 mM permolybdate would inhibit
both. A pseudonormal balance would then be estab-
lished. These PTPases do not need to have Cx43 as
their direct substrate, although the rapid reversibility
of the altered Cx43 band pattern induced by 100 mM
permolybdate suggests the action of a phosphatase.
We have previously shown that the altered Cx43
band pattern after exposure to 300 mM permolybdate
for 30 min is mainly due to tyrosine phosphorylation
 .Mikalsen et al., submitted . The two-PTPase-argu-
ment may also explain the biphasic response on
cellular tyrosine phosphorylation. It remains to be
seen if a similar biphasic dose-response induced by
permolybdate can be found in other systems. The
partial differences between pervanadate and per-
molybdate in mimicking interferong-like signal trans-
w xduction 32 could be due to both a biphasic response
to permolybdate and a sub-optimal generation of the
compound. The biphasic response pattern for per-
molybdate may imply that permolybdate inhibits a
 .different but overlapping complement of PTPases
than does pervanadate. Alternatively, it may be ex-
plained by a more rapid reaction with the target
enzymes causing inhibition, but the enzymes are also
 .faster reactivated or regenerated after inhibition by
permolybdate compared to the inhibition caused by
pervanadate. In addition, we note that the two-
PTPase-argument also may explain the delayed de-
crease in GJIC caused by 1000 mM permolybdate
 .Fig. 3 if the less sensitive PTPase is faster reacti-
vated than the more sensitive PTPase.
4.3. Partial dissociation between decreased GJIC
and altered Cx43 band pattern
Decreased GJIC has in many cases been correlated
w xwith changes in Cx43 phosphorylation status 52–54 .
On the other hand, some compounds may inhibit
GJIC without a concurrent change in Cx43 band
w xpattern 55 . Even the potent protein kinase C activa-
tor 12-O-tetradecanoylphorbol 13-acetate may inhibit
GJIC in SHE cells without any major changes in
Cx43 band pattern, while the change is strong in V79
w xcells 15 . We report here that major changes in the
Cx43 band pattern may occur without a concurrent
decrease in GJIC. The changes in Cx43 band pattern
were strong after 15–30 min of exposure to 100, 300
or 1000 mM permolybdate. Yet, GJIC did not show
any decrease for 1000 mM permolybdate at 15 and
30 min. In contrast, GJIC decreased strongly after 30
min exposure to 300 mM permolybdate, and 100 mM
showed an intermediate response on GJIC. Appar-
ently, the Cx43 band pattern was partially normalized
after 90–120 min of exposure to 1000 mM per-
molybdate, but GJIC decreased strongly at these
points of time. The NPrP1rP2 bands reappeared to
some degree, but there was a new broad band be-
tween the NP and P1 bands. These results imply that
changes in the phosphorylation status of Cx43 as
detected by Western blotting may not always predict
the corresponding GJIC response even during regi-
mens that modulate the phosphorylation balance.
Several explanations can be offered for the dissoci-
ation between altered band pattern of Cx43 and de-
creased GJIC. They are not mutually excluding. First,
the NP species is probably not involved in functional
w xcommunication, while the P1 and P2 species are 56 .
Since the NP species largely disappear after exposure
to 1000 mM permolybdate for 15–60 min, this species
can become phosphorylated without a concomitant
decrease in GJIC. With the present techniques, the
 .modified previous NP species migrates in the same
area as the P1rP2 species, and partially covers these
two species. Possibly, there is no alteration in the
phosphorylation status of the P1 and P2 species and
thereby no alterations of GJIC.
Second, accessory proteins may be involved in the
regulation of GJIC. SH2 and SH3 domain proteins
w xare currently much studied 57 . The SH2 domain
proteins bind to specific phosphotyrosine containing
w xsequences 58 . We do not yet know which tyrosine
residues of Cx43 that become phosphorylated under
the influence of permolybdate and the other percom-
 .pounds Mikalsen et al., submitted . Cx43 Y265 has
been implicated as a phosphorylation site for v-Src
w x35 . Rat Cx43 contains the sequence YFNG at
w xresidues 267-270 22 . The Grb2rSem-5 SH2 con-
w xsensus binding sequence is pYXNX 58 . SH2 and
SH3 domains are often present in the same protein. It
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w xis therefore interesting that Sparks et al. 59 recently
found bovine Cx44 to contain a sequence that poten-
tially could bind the SH3 domains of Src and phos-
pholipase C see http:rrwww.unc.edu.rdeptsrbi-
.ologyrkeyref.html . Cx43 contains potential SH3
 .binding sequences PXXP on either side of YFNG;
PLSPSK at residues 253–258, and SSPTAPLSPM-
SPPGY at residues 272–286. The former sequence
has resemblance of many Grb2 SH3 binding se-
 w x.quences, PXXPXKrR Fig. 3 in Ref. 59 . In addi-
 .tion, SPPGY residues 282–286 conforms to the
consensus binding sequence XPPXY for WW domain
w xproteins 60 . This sequence contains a potential site
for phosphorylation, making a possibility for compe-
tition between WW, SH2 and SH3 domain proteins
w x61 . We also note that the PXSP sequences in Cx43
 .residues 253–256, 277–280 and 280–283 may be
w xphosphorylation sites for a MAP kinase 62 . Specula-
tively, the Cx43 residues 253–286 may function as
an integration site for serine kinases, tyrosine kinases
and binding proteins involved in the regulation of
GJIC. Other connexins do not seem to contain such a
heavy concentration of potential interaction sites.
However, calmodulin and other calcium modulated
proteins bind to purified proteins from gap junctions
of rat liver, bovine lens, and crayfish hepatopancreas
w x  .63,64 . If the accessory protein s are sequestered
elsewhere in the cell by other proteins that also
become tyrosine phosphorylated as a consequence of
the permolybdate treatment, GJIC would not be af-
fected in spite of altered phosphorylation status of
Cx43.
Third, since only of a part of the connexin family
has been investigated in SHE cells, it remains the
formal possibility that other connexins could partially
account for the dissociation between GJIC and Cx43
band shifts. However, this would not explain the
biphasic dose-response for permolybdate.
In summary, the major conclusions of the present
 .work are: i Molybdate can be used to generate a
permolybdate compound that strongly increases the
amount of phosphotyrosine in intact cells and concur-
 .rently decreases GJIC. ii Permolybdate is probably
 .a Mo VI compound that contains two peroxide lig-
ands when generated under slightly acidic conditions.
 .iii Pervanadate and permolybdate have partly differ-
ent cellular effects, implying the possibility of inhibi-
tion of different, but overlapping, complements of
.PTPases. iv Under certain conditions, permolybdate
revealed a dissociation between altered Cx43 band
pattern in Western blots and the functional GJIC.
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